Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Cancer Conference Journal

07-05-2024 | Hepatocellular Carcinoma | Case Report - Surgery

A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response

Authors: Masayuki Okuno, Hideko Ohama, Ikuo Nakamura, Makoto Yoshida, Daisuke Shirai, Takahito Hirai, Hiroaki Fuji, Ami Kurimoto, Tomohiro Okamoto, Hideaki Sueoka, Kenjiro Iida, Masaharu Tada, Takako Kihara, Hironori Tanaka, Seiko Hirono

Published in: International Cancer Conference Journal

Login to get access

Abstract

Here, we present a patient with hepatocellular carcinoma complicated by tumor thrombosis into the main portal trunk and perihepatic lymph node metastases who was treated with atezolizumab plus bevacizumab. Shrinkage of the main tumor, portal vein thrombosis, and lymph node metastases were achieved; therefore, hepatectomy with lymphadenectomy could be performed. Final pathology indicated a complete pathological response in the main tumor, portal vein thrombosis, and perihepatic lymph nodes. The patient is currently alive with no evidence of recurrence on radiological assessment at 3 months after surgery.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424CrossRefPubMed
2.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681–693CrossRefPubMed
3.
Hasegawa K, Takemura N, Yamashita T, Watadani T, Kaibori M, Kubo S et al (2023) Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC guidelines). Hepatol Res 53(5):383–390CrossRefPubMed
4.
5.
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905CrossRefPubMed
6.
Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J et al (2022) Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol 40(4_suppl):379
7.
Okuno M, Ishii T, Ichida A, Soyama A, Takemura N, Hirono S et al (2023) Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab. BMC Cancer 23(1):780CrossRefPubMedPubMedCentral
8.
Japan LCSGo (2010) General rules for the clinical and pathological study of primary liver cancer, 3 edn. Kanehara & Co., Ltd., Tokyo
9.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247
10.
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60CrossRefPubMed
11.
Yasui Y, Tsuchiya K, Kurosaki M, Takeguchi T, Takeguchi Y, Okada M et al (2018) Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. Hepatol Res 48(6):442–450CrossRefPubMed
12.
Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H et al (2023) Achievement of complete response and drug-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study. Liver Cancer 12(4):321–338CrossRefPubMedPubMedCentral
13.
Hoshino T, Naganuma A, Furusawa A, Suzuki Y, Hirai K, Sakamoto I et al (2022) A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment. Clin J Gastroenterol 15(4):776–783CrossRefPubMed
14.
Kurisaki K, Soyama A, Hara T, Matsushima H, Imamura H, Tanaka T et al (2023) Pathologic complete response after chemotherapy with atezolizumab plus bevacizumab for hepatocellular carcinoma with tumor thrombus in the main portal trunk. Dig Surg 40(1–2):84–89CrossRefPubMed
15.
Fukunaga A, Takata K, Itoh S, Yamauchi R, Tanaka T, Yokoyama K et al (2023) Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis. Clin J Gastroenterol 16(2):224–228CrossRefPubMed
16.
Miyata T, Sugi K, Horino T, Ono A, Tagayasu Y, Nomoto D et al (2023) Conversion surgery after atezolizumab plus bevacizumab for primary and peritoneal metastasis after hepatocellular carcinoma rupture. Anticancer Res 43(2):943–947CrossRefPubMed
17.
Shindoh J, Kawamura Y, Kobayashi Y, Kobayashi M, Akuta N, Okubo S et al (2021) prognostic impact of surgical intervention after lenvatinib treatment for advanced hepatocellular carcinoma. Ann Surg Oncol 28(12):7663–7672CrossRefPubMed
18.
Okuno M, Hatano E, Tada M, Nishimura T, Okamoto T, Sueoka H et al (2024) Surgical intervention after lenvatinib treatment in patients with advanced hepatocellular carcinoma. Anticancer Res 44(4):1727–1737CrossRefPubMed
19.
20.
Elsholtz FHJ, Asbach P, Haas M, Becker M, Beets-Tan RGH, Thoeny HC et al (2021) Introducing the node reporting and data system 1.0 (node-RADS): a concept for standardized assessment of lymph nodes in cancer. Eur Radiol 31(8):6116–6124
Metadata
Title
A patient who underwent conversion surgery after atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein thrombosis and perihepatic lymph node metastases achieved a pathological complete response
Authors
Masayuki Okuno
Hideko Ohama
Ikuo Nakamura
Makoto Yoshida
Daisuke Shirai
Takahito Hirai
Hiroaki Fuji
Ami Kurimoto
Tomohiro Okamoto
Hideaki Sueoka
Kenjiro Iida
Masaharu Tada
Takako Kihara
Hironori Tanaka
Seiko Hirono
Publication date
07-05-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00683-5
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits